Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908932 · ClinicalTrials.gov registry record · NA
Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's
A NA study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- NA
- Development phase
- 555
- Enrollment target
NCT02908932: Completed NA study, sponsored by Medical University of South Carolina.
NCT02908932 is a NA study that has completed, run by Medical University of South Carolina. The registered enrollment target is 555 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02908932, a NA study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- NA
- Development phase
- 555 participants
- Enrollment target
Study Summary
The goal of this study is to determine if supplementation with krill oil concentrate containing the phospholipid-bound omega-3 fatty acids improves performance on specific cognitive tests that underlie key elements in U.S. Army Infantry Basic Officer Leaders Course (IBOLC) and in Ranger School (Training) at Fort Benning, Georgia (GA).
Primary Outcome
Stroop
Interventions
- DIETARY_SUPPLEMENT Placebo supplement
- DIETARY_SUPPLEMENT Phospholipid-bound omega-3 supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-06 |
| Phase | NA |
What the finished NCT02908932 record still lists
NCT02908932 is an interventional study that assigns participants to a tested intervention. The registered 555 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo supplement is the first listed.
NCT02908932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02908932 about?
NCT02908932 is a clinical study titled "Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's". The goal of this study is to determine if supplementation with krill oil concentrate containing the phospholipid-bound omega-3 fatty acids improves performance on specific cognitive tests that underlie key elements in U.S. Army Infantry Basic Officer Leaders Course (IBOLC) and in Ranger School (Trai...
What is the current status of trial NCT02908932?
This trial is currently completed. It is a NA study. The enrollment target is 555 participants. The study started on 2016-08. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02908932?
The interventions under investigation include: Placebo supplement (DIETARY_SUPPLEMENT), Phospholipid-bound omega-3 supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02908932?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02908932's enrollment target sits among peer trials
555 184th of 2000 higher than 1,817 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia